Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock
CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.01−0.37 (-10.81%)
Close on Nov 17, 2026Market cap $58.22MP/E –Yield –
Corbus Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Corbus Pharmaceuticals's total assets was $126.99M at Jun 30, 2026. For fiscal 2025 it was $168.20M, up 7.9% from the year before. Over ten years it grew 29.3% a year on average. The highest annual figure on record is $168.20M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.20M | +7.9% |
| FY2024 | Dec 31, 2024 | $155.88M | +451.4% |
| FY2023 | Dec 31, 2023 | $28.27M | -57.4% |
| FY2022 | Dec 31, 2022 | $66.31M | -38.4% |
| FY2021 | Dec 31, 2021 | $107.73M | +5.3% |
| FY2020 | Dec 31, 2020 | $102.29M | +108.2% |
| FY2019 | Dec 31, 2019 | $49.14M | +4.6% |
| FY2018 | Dec 31, 2018 | $46.99M | -29.8% |
| FY2017 | Dec 31, 2017 | $66.98M | +274.4% |
| FY2016 | Dec 31, 2016 | $17.89M | +38.9% |
| FY2015 | Dec 31, 2015 | $12.88M | +95.1% |
| FY2014 | Dec 31, 2014 | $6.60M | +2060.5% |
| FY2013 | Dec 31, 2013 | $305.52K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $126.99M | +1.5% |
| Q1 FY2026 | Mar 31, 2026 | $144.48M | +3.3% |
| Q4 FY2025 | Dec 31, 2025 | $168.20M | +7.9% |
| Q3 FY2025 | Sep 30, 2025 | $109.51M | -33.3% |
| Q2 FY2025 | Jun 30, 2025 | $125.09M | -17.7% |
| Q1 FY2025 | Mar 31, 2025 | $139.93M | +11.3% |
| Q4 FY2024 | Dec 31, 2024 | $155.88M | +451.4% |
| Q3 FY2024 | Sep 30, 2024 | $164.17M | +352.5% |
| Q2 FY2024 | Jun 30, 2024 | $151.98M | +247.6% |
| Q1 FY2024 | Mar 31, 2024 | $125.74M | +143.5% |
| Q4 FY2023 | Dec 31, 2023 | $28.27M | -57.4% |
| Q3 FY2023 | Sep 30, 2023 | $36.28M | -50.9% |
| Q2 FY2023 | Jun 30, 2023 | $43.72M | -46.7% |
| Q1 FY2023 | Mar 31, 2023 | $51.65M | -46.0% |
| Q4 FY2022 | Dec 31, 2022 | $66.31M | -38.4% |
| Q3 FY2022 | Sep 30, 2022 | $73.83M | -38.3% |
| Q2 FY2022 | Jun 30, 2022 | $82.07M | -32.0% |
| Q1 FY2022 | Mar 31, 2022 | $95.68M | -31.7% |
| Q4 FY2021 | Dec 31, 2021 | $107.73M | +5.3% |
| Q3 FY2021 | Sep 30, 2021 | $119.57M | +24.8% |
| Q2 FY2021 | Jun 30, 2021 | $120.61M | +22.9% |
| Q1 FY2021 | Mar 31, 2021 | $140.15M | +114.9% |
| Q4 FY2020 | Dec 31, 2020 | $102.29M | +108.2% |
| Q3 FY2020 | Sep 30, 2020 | $95.84M | +40.7% |
| Q2 FY2020 | Jun 30, 2020 | $98.12M | +16.6% |
| Q1 FY2020 | Mar 31, 2020 | $65.20M | -35.7% |
| Q4 FY2019 | Dec 31, 2019 | $49.14M | +4.6% |
| Q3 FY2019 | Sep 30, 2019 | $68.13M | +11.4% |
| Q2 FY2019 | Jun 30, 2019 | $84.12M | +19.7% |
| Q1 FY2019 | Mar 31, 2019 | $101.39M | +31.4% |
| Q4 FY2018 | Dec 31, 2018 | $46.99M | -29.8% |
| Q3 FY2018 | Sep 30, 2018 | $61.18M | +59.2% |
| Q2 FY2018 | Jun 30, 2018 | $70.29M | +57.7% |
| Q1 FY2018 | Mar 31, 2018 | $77.14M | +52.4% |
| Q4 FY2017 | Dec 31, 2017 | $66.98M | +274.4% |
| Q3 FY2017 | Sep 30, 2017 | $38.42M | +94.5% |
| Q2 FY2017 | Jun 30, 2017 | $44.56M | – |
| Q1 FY2017 | Mar 31, 2017 | $50.61M | – |
| Q4 FY2016 | Dec 31, 2016 | $17.89M | – |
| Q3 FY2016 | Sep 30, 2016 | $19.76M | – |
See a number that looks wrong?